Last Updated: July 22, 2026

TEZRULY Drug Patent Profile

Name: TEZRULY Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

When do Tezruly patents expire, and what generic alternatives are available?

Tezruly is a drug marketed by Novitium Pharma and is included in one NDA. There are two patents protecting this drug.

The generic ingredient in TEZRULY is terazosin hydrochloride. There are twenty-four drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the terazosin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tezruly

A generic version of TEZRULY was approved as terazosin hydrochloride by SENORES PHARMS on March 30^th, 1998.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for TEZRULY?
What are the global sales for TEZRULY?
What is Average Wholesale Price for TEZRULY?

Summary for TEZRULY

US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Applications:	1,462
What excipients (inactive ingredients) are in TEZRULY?	TEZRULY excipients list
DailyMed Link:	TEZRULY at DailyMed

Drug patent expirations by year for TEZRULY

Pharmacology for TEZRULY

Drug Class	alpha-Adrenergic Blocker
Mechanism of Action	Adrenergic alpha-Antagonists

US Patents and Regulatory Information for TEZRULY

TEZRULY is protected by four US patents.

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novitium Pharma	TEZRULY	terazosin hydrochloride	SOLUTION;ORAL	218139-001	Jul 29, 2024		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial	Y			⤷ Start Trial
Novitium Pharma	TEZRULY	terazosin hydrochloride	SOLUTION;ORAL	218139-001	Jul 29, 2024		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.